3,4-Methylenedioxy-methamphetamine induces in vivo regional up-regulation of central nicotinic receptors in rats and potentiates the regulatory effects of nicotine on these receptors

NeuroToxicology

Volumn 35, Issue 1, 2013, Pages 41-49

  Pubill, David ^a   Garcia Ratés, Sara ^a   Camarasa, Jordi ^a   Escubedo, Elena ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Ecstasy; Epibatidine; MDMA; Nicotine; Nicotinic; Up regulation

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; EPIBATIDINE; METHYLLYCACONITINE; NICOTINE; NICOTINIC RECEPTOR ALPHA4; NICOTINIC RECEPTOR BETA2; PAROXETINE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG ABUSE; GENICULATE NUCLEUS; HIPPOCAMPUS; IN VIVO STUDY; MALE; MESENCEPHALON; NEUROMODULATION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; RECEPTOR DENSITY; RECEPTOR UPREGULATION; SUBSTANTIA NIGRA; SUPERIOR COLLICULUS; TISSUE SPECIFICITY; VENTRAL TEGMENTUM;

ACONITINE; ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; BLOTTING, WESTERN; BRAIN; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; IMMUNOPRECIPITATION; INJECTIONS, SUBCUTANEOUS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NICOTINE; NICOTINIC AGONISTS; PAROXETINE; PYRIDINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TIME FACTORS; UP-REGULATION;

NICOTIANA TABACUM; RATTUS;

EID: 84872447969     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2012.11.008     Document Type: Article

References (59)

1. Adamaszek M., Khaw A.V., Buck U., Andresen B., Thomasius R. Evidence of neurotoxicity of ecstasy: sustained effects on electroencephalographic activity in polydrug users. PLoS ONE 2010, 5:e14097.
2. Albuquerque E.X., Pereira E.F., Alkondon M., Rogers S.W. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 2009, 89:73-120.
3. Battaglia G., Yeh S.Y., O'Hearn E., Molliver M.E., Kuhar M.J., De Souza E.B. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther 1987, 242:911-916.
4. Biezonski D.K., Meyer J.S. Effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin transporter and vesicular monoamine transporter 2 protein and gene expression in rats: implications for MDMA neurotoxicity. J Neurochem 2010, 112:951-962.
5. Biezonski D.K., Meyer J.S. The nature of 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonergic dysfunction: evidence for and against the neurodegeneration hypothesis. Curr Neuropharmacol 2011, 9:84-90.
6. Broening H.W., Bowyer J.F., Slikker W. Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (+/-)-3,4-methylenedioxymethamphetamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response. J Pharmacol Exp Ther 1995, 275:325-333.
7. Camarasa J., Marimon J.M., Rodrigo T., Escubedo E., Pubill D. Memantine prevents the cognitive impairment induced by 3,4-methylenedioxymethamphetamine in rats. Eur J Pharmacol 2008, 589:132-139.
8. Capela J.P., Carmo H., Remiao F., Bastos M.L., Meisel A., Carvalho F. Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol Neurobiol 2009, 39:210-271.
9. Chipana C., Camarasa J., Pubill D., Escubedo E. Protection against MDMA-induced dopaminergic neurotoxicity in mice by methyllycaconitine: involvement of nicotinic receptors. Neuropharmacology 2006, 51:885-895.
10. Chipana C., Camarasa J., Pubill D., Escubedo E. Memantine prevents MDMA-induced neurotoxicity. Neurotoxicology 2008, 29:179-183.
11. Chipana C., Torres I., Camarasa J., Pubill D., Escubedo E. Memantine protects against amphetamine derivatives-induced neurotoxic damage in rodents. Neuropharmacology 2008, 54:1254-1263.
12. Chipana C., Garcia-Rates S., Camarasa J., Pubill D., Escubedo E. Different oxidative profile and nicotinic receptor interaction of amphetamine and 3,4-methylenedioxy-methamphetamine. Neurochem Int 2008, 52:401-410.
13. Davies A.R., Hardick D.J., Blagbrough I.S., Potter B.V., Wolstenholme A.J., Wonnacott S. Characterisation of the binding of [3H]methyllycaconitine: a new radioligand for labelling alpha 7-type neuronal nicotinic acetylcholine receptors. Neuropharmacology 1999, 38:679-690.
14. Erritzoe D., Frokjaer V.G., Holst K.K., Christoffersen M., Johansen S.S., Svarer C., et al. In vivo imaging of cerebral serotonin transporter and serotonin (2A) receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or " ecstasy" ) and hallucinogen users. Arch Gen Psychiatry 2011, 68:562-576.
15. Escubedo E., Abad S., Torres I., Camarasa J., Pubill D. Comparative neurochemical profile of 3,4-methylenedioxymethamphetamine and its metabolite alpha-methyldopamine on key targets of MDMA neurotoxicity. Neurochem Int 2011, 58:92-101.
16. Even N., Cardona A., Soudant M., Corringer P.J., Changeux J.P., Cloez-Tayarani I. Regional differential effects of chronic nicotine on brain alpha 4-containing and alpha 6-containing receptors. Neuroreport 2008, 19:1545-1550.
17. Fenster C.P., Hicks J.H., Beckman M.L., Covernton P.J., Quick M.W., Lester R.A. Desensitization of nicotinic receptors in the central nervous system. Ann N Y Acad Sci 1999, 868:620-623.
18. Flores C.M., Rogers S.W., Pabreza L.A., Wolfe B.B., Kellar K.J. A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol 1992, 41:31-37.
19. Francis H.M., Kraushaar N.J., Hunt L.R., Cornish J.L. Serotonin 5-HT4 receptors in the nucleus accumbens are specifically involved in the appetite suppressant and not locomotor stimulant effects of MDMA ('ecstasy'). Psychopharmacology (Berl) 2011, 213:355-363.
20. Gaimarri A., Moretti M., Riganti L., Zanardi A., Clementi F., Gotti C. Regulation of neuronal nicotinic receptor traffic and expression. Brain Res Rev 2007, 55:134-143.
21. Garcia-Rates S., Camarasa J., Escubedo E., Pubill D. Methamphetamine and 3,4-methylenedioxymethamphetamine interact with central nicotinic receptors and induce their up-regulation. Toxicol Appl Pharmacol 2007, 223:195-205.
22. Garcia-Rates S., Camarasa J., Sanchez-Garcia A.I., Gandia L., Escubedo E., Pubill D. The effects of 3,4-methylenedioxymethamphetamine (MDMA) on nicotinic receptors: intracellular calcium increase, calpain/caspase 3 activation, and functional upregulation. Toxicol Appl Pharmacol 2010, 244:344-353.
23. Gopalakrishnan M., Molinari E.J., Sullivan J.P. Regulation of human alpha4beta2 neuronal nicotinic acetylcholine receptors by cholinergic channel ligands and second messenger pathways. Mol Pharmacol 1997, 52:524-534.
24. Gordon C.J., Watkinson W.P., O'Callaghan J.P., Miller D.B. Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat. Pharmacol Biochem Behav 1991, 38:339-344.
25. Gotti C., Moretti M., Gaimarri A., Zanardi A., Clementi F., Zoli M. Heterogeneity and complexity of native brain nicotinic receptors. Biochem Pharmacol 2007, 74:1102-1111.
26. Govind A.P., Vezina P., Green W.N. Nicotine-induced upregulation of nicotinic receptors: underlying mechanisms and relevance to nicotine addiction. Biochem Pharmacol 2009, 78:756-765.
27. Green A.R., O'Shea E., Saadat K.S., Elliott J.M., Colado M.I. Studies on the effect of MDMA ('ecstasy') on the body temperature of rats housed at different ambient room temperatures. Br J Pharmacol 2005, 146:306-312.
28. Hansen J.P., Riddle E.L., Sandoval V., Brown J.M., Gibb J.W., Hanson G.R., et al. Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity. J Pharmacol Exp Ther 2002, 300:1093-1100.
29. Johnson E.A., O'Callaghan J.P., Miller D.B. Brain concentrations of d-MDMA are increased after stress. Psychopharmacology (Berl) 2004, 173:278-286.
30. Kuryatov A., Luo J., Cooper J., Lindstrom J. Nicotine acts as a pharmacological chaperone to up-regulate human alpha4beta2 acetylcholine receptors. Mol Pharmacol 2005, 68:1839-1851.
31. Lester H.A., Xiao C., Srinivasan R., Son C.D., Miwa J., Pantoja R., et al. Nicotine is a selective pharmacological chaperone of acetylcholine receptor number and stoichiometry. Implications for drug discovery. AAPS J 2009, 11:167-177.
32. Levin E.D., Rezvani A.H. Nicotinic treatment for cognitive dysfunction. Curr Drug Targets CNS Neurol Disord 2002, 1:423-431.
33. Malberg J.E., Seiden L.S. Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci 1998, 18:5086-5094.
34. Mao D., Perry D.C., Yasuda R.P., Wolfe B.B., Kellar K.J. The alpha4beta2alpha5 nicotinic cholinergic receptor in rat brain is resistant to up-regulation by nicotine in vivo. J Neurochem 2008, 104:446-456.
35. Marks M.J., Clure-Begley T.D., Whiteaker P., Salminen O., Brown R.W., Cooper J., et al. Increased nicotinic acetylcholine receptor protein underlies chronic nicotine-induced up-regulation of nicotinic agonist binding sites in mouse brain. J Pharmacol Exp Ther 2011, 337:187-200.
36. Marks M.J., Stitzel J.A., Romm E., Wehner J.M., Collins A.C. Nicotinic binding sites in rat and mouse brain: comparison of acetylcholine, nicotine, and alpha-bungarotoxin. Mol Pharmacol 1986, 30:427-436.
37. Martin L.F., Kem W.R., Freedman R. Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology (Berl) 2004, 174:54-64.
38. Nguyen H.N., Rasmussen B.A., Perry D.C. Subtype-selective up-regulation by chronic nicotine of high-affinity nicotinic receptors in rat brain demonstrated by receptor autoradiography. J Pharmacol Exp Ther 2003, 307:1090-1097.
39. Nulsen C.E., Fox A.M., Hammond G.R. Differential effects of ecstasy on short-term and working memory: a meta-analysis. Neuropsychol Rev 2010, 20:21-32.
40. O'Shea E., Granados R., Esteban B., Colado M.I., Green A.R. The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy'). Neuropharmacology 1998, 37:919-926.
41. O'Shea E., Orio L., Escobedo I., Sanchez V., Camarero J., Green A.R., et al. MDMA-induced neurotoxicity: long-term effects on 5-HT biosynthesis and the influence of ambient temperature. Br J Pharmacol 2006, 148:778-785.
42. Parrott A.C., Lees A., Garnham N.J., Jones M., Wesnes K. Cognitive performance in recreational users of MDMA of 'ecstasy': evidence for memory deficits. J Psychopharmacol 1998, 12:79-83.
43. Pauly J.R., Marks M.J., Robinson S.F., van de Kamp J.L., Collins A.C. Chronic nicotine and mecamylamine treatment increase brain nicotinic receptor binding without changing alpha 4 or beta 2 mRNA levels. J Pharmacol Exp Ther 1996, 278:361-369.
44. Peng X., Gerzanich V., Anand R., Whiting P.J., Lindstrom J. Nicotine-induced increase in neuronal nicotinic receptors results from a decrease in the rate of receptor turnover. Mol Pharmacol 1994, 46:523-530.
45. Picciotto M.R., Zoli M., Changeux J.P. Use of knock-out mice to determine the molecular basis for the actions of nicotine. Nicotine Tob Res 1999, 1(Suppl. 2):S121-S125.
46. Pubill D., Canudas A.M., Pallas M., Camins A., Camarasa J., Escubedo E. Different glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity. Naunyn Schmiedebergs Arch Pharmacol 2003, 367:490-499.
47. Quednow B.B., Jessen F., Kuhn K.U., Maier W., Daum I., Wagner M. Memory deficits in abstinent MDMA (ecstasy) users: neuropsychological evidence of frontal dysfunction. J Psychopharmacol 2006, 20:373-384.
48. Reneman L., Endert E., de Bruin K., Lavalaye J., Feenstra M.G., de Wolff F.A., et al. The acute and chronic effects of MDMA (" ecstasy" ) on cortical 5-HT2A receptors in rat and human brain. Neuropsychopharmacology 2002, 26:387-396.
49. Ripoll N., Bronnec M., Bourin M. Nicotinic receptors and schizophrenia. Curr Med Res Opin 2004, 20:1057-1074.
50. Sallette J., Pons S., Devillers-Thiery A., Soudant M., Prado d.C., Changeux J.P., et al. Nicotine upregulates its own receptors through enhanced intracellular maturation. Neuron 2005, 46:595-607.
51. Schnoll R.A., Wileyto E.P., Lerman C. Extended duration therapy with transdermal nicotine may attenuate weight gain following smoking cessation. Addict Behav 2012, 37:565-568.
52. Scholey A.B., Parrott A.C., Buchanan T., Heffernan T.M., Ling J., Rodgers J. Increased intensity of Ecstasy and polydrug usage in the more experienced recreational ecstasy/MDMA users: a WWW study. Addict Behav 2004, 29:743-752.
53. Srinivasan R., Pantoja R., Moss F.J., Mackey E.D., Son C.D., Miwa J., et al. Nicotine up-regulates alpha4beta2 nicotinic receptors and ER exit sites via stoichiometry-dependent chaperoning. J Gen Physiol 2011, 137:59-79.
54. Tribollet E., Bertrand D., Marguerat A., Raggenbass M. Comparative distribution of nicotinic receptor subtypes during development, adulthood and aging: an autoradiographic study in the rat brain. Neuroscience 2004, 124:405-420.
55. Turner J.R., Kellar K.J. Nicotinic cholinergic receptors in the rat cerebellum: multiple heteromeric subtypes. J Neurosci 2005, 25:9258-9265.
56. Vallejo Y.F., Buisson B., Bertrand D., Green W.N. Chronic nicotine exposure upregulates nicotinic receptors by a novel mechanism. J Neurosci 2005, 25:5563-5572.
57. Walsh H., Govind A.P., Mastro R., Hoda J.C., Bertrand D., Vallejo Y., et al. Up-regulation of nicotinic receptors by nicotine varies with receptor subtype. J Biol Chem 2008, 283:6022-6032.
58. Werkheiser J.L., Sydserff S., Hubbs S.J., Ding M., Eisman M.S., Perry D., et al. Ultra-low exposure to alpha-7 nicotinic acetylcholine receptor partial agonists elicits an improvement in cognition that corresponds with an increase in alpha-7 receptor expression in rodents: implications for low dose clinical efficacy. Neuroscience 2011, 186:76-87.
59. Yamamoto B.K., Raudensky J. The role of oxidative stress, metabolic compromise, and inflammation in neuronal injury produced by amphetamine-related drugs of abuse. J Neuroimmune Pharmacol 2008, 3:203-217.